NCT04746430

COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study

COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study: an Open-label Randomized Controlled Trial

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: General Practitioners Research Institute · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The COVID-19 coronavirus has led to a global pandemic of respiratory diseases with an increase in hospitalization and death risk. To keep COVID-19 manageable for healthcare, early treatment is urgently needed to avoid hospitalization. Dexamethasone can dampen the exaggerated cytokine response to COVID-19 and is a promising agent for preventing disease aggravation, hospitalization and death. However, the evidence on the effectiveness, safety and cost-effectiveness of dexamethasone treatment in primary care is inconclusive.

Conditions

• Covid19
• Corona Virus Infection

Interventions

Type	Name	Description
DRUG	Dexamethasone	6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms

Timeline

• Start date: 2021-02-16
• Primary completion: 2021-04-23
• Completion: 2021-04-23
• First posted: 2021-02-09
• Last updated: 2021-05-11

Locations

1 site across 1 country: Netherlands